Ignite Creation Date:
2025-12-25 @ 4:52 AM
Ignite Modification Date:
2025-12-26 @ 3:53 AM
Study NCT ID:
NCT04142918
Status:
UNKNOWN
Last Update Posted:
2020-03-25
First Post:
2019-10-25
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Diagnostic Markers of Neuropathic Odontalgia
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009437', 'term': 'Neuralgia'}], 'ancestors': [{'id': 'D010523', 'term': 'Peripheral Nervous System Diseases'}, {'id': 'D009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D010146', 'term': 'Pain'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'Oral mucosa biopsy'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'CROSS_SECTIONAL', 'observationalModel': 'OTHER'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 45}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2020-06-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-03', 'completionDateStruct': {'date': '2021-03-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2020-03-24', 'studyFirstSubmitDate': '2019-10-25', 'studyFirstSubmitQcDate': '2019-10-25', 'lastUpdatePostDateStruct': {'date': '2020-03-25', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-10-29', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2020-12-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Patched-1 Western Blot concentration', 'timeFrame': 'Baseline', 'description': 'Patched-1 will be measured in oral mucosa/gingiva samples using Western Blot'}, {'measure': 'Patched-1 immunohistochemistry concentration', 'timeFrame': 'Baseline', 'description': 'Patched-1 will be measured in oral mucosa/gingiva samples using immunohistochemistry (IHC)'}, {'measure': 'Patched-1 ELISA concentration', 'timeFrame': 'Baseline', 'description': 'Patched-1 will be measured in oral mucosa/gingiva samples using ELISA'}, {'measure': 'Frizzled-7 Western Blot concentration', 'timeFrame': 'Baseline', 'description': 'Frizzled-7 will be measured in oral mucosa/gingiva samples using Western Blot'}, {'measure': 'Frizzled-7 immunohistochemistry concentration', 'timeFrame': 'Baseline', 'description': 'Frizzled-7 will be measured in oral mucosa/gingiva samples using immunohistochemistry (IHC)'}, {'measure': 'Frizzled-7 ELISA concentration', 'timeFrame': 'Baseline', 'description': 'Frizzled-7 will be measured in oral mucosa/gingiva samples using ELISA'}, {'measure': 'Claudin-5 Western Blot concentration', 'timeFrame': 'Baseline', 'description': 'Claudin-5 will be measured in oral mucosa/gingiva samples using Western Blot'}, {'measure': 'Claudin-5 immunohistochemistry concentration', 'timeFrame': 'Baseline', 'description': 'Claudin-5 will be measured in oral mucosa/gingiva samples using immunohistochemistry (IHC)'}, {'measure': 'Claudin-5 ELISA concentration', 'timeFrame': 'Baseline', 'description': 'Claudin-5 will be measured in oral mucosa/gingiva samples using ELISA'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['painful post-traumatic trigeminal neuropathy', 'neuropathic pain', 'neuropathic odontalgia', 'gingival biopsy'], 'conditions': ['Oral Mucosa']}, 'descriptionModule': {'briefSummary': 'The DIAMOND study aims to investigate the presence and diagnostic relevance of potential biomarkers of the blood-nerve barrier disruption as surrogate markers of painful post-traumatic trigeminal neuropathic pain in patients presenting with neuropathic odontalgia. The first part of the study explores the proof-of-concept and technical feasibility of intra-epithelial nerve fiber immunostaining in gingival/oral mucosa biopsies and the potential presence of these biomarkers in healthy patients (baseline condition).', 'detailedDescription': 'Painful Post-Traumatic Trigeminal Neuropathy (PPTTN) defines a neuropathic painful condition affecting the orofacial region, following local nerve trauma, usually secondary to dental treatments (tooth avulsion, root canal treatments….). It often presents as odontalgia of atypical presentation, unresponsive to conventional treatments. The diagnostic is often complex (and often is a diagnosis of elimination), leading to unnecessary iatrogenic dental treatments and insufficient pain relief.\n\nThis study aims to explore potential new markers of PPTTN, based on a translational approach following previous preclinical work that showed the importance of the disruption of the blood-nerve barrier in generating post-traumatic neuropathic pain. Several markers of such disruption have been highlighted (such as Claudin-5, Patched-1 and Frizzled-7) that could be specifically downregulated in neuropathic pain conditions (as compared to inflammatory neuritis conditions). As such, these markers could be interesting biomarkers of neuropathic pain. This study aims to explore the presence (and absence) of such markers in healthy vs neuropathic patients respectively.\n\nThe first part of the study investigates the technical feasibility of intra-epithelial nerve fiber staining in oral mucosa/gingiva specimens collected in healthy patients (undergoing routine oral surgery procedures) and the immunoreactivity/presence of such biomarkers in those specimens.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'patients requiring an oral/dental surgical intervention that will generate gingival/mucosal tissue elimination (as part of the normal surgical procedure)', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nAdult patients (over 18 years old) requiring an oral/dental surgical intervention that will generate gingival/mucosal tissue elimination (as part of the normal surgical procedure)\n\nExclusion Criteria:\n\n* Patient with a diagnosed odontalgia\n* Patient with Painful Post-Traumatic Trigeminal Neuropathy (PPTTN)\n* Patient with unexplained pains or a neuropathic pain regardless of its location\n* Patient under guardianship or trusteeship\n* Patient who refuses to give his/her non-opposition to participate to the study'}, 'identificationModule': {'nctId': 'NCT04142918', 'acronym': 'DIAMOND-1', 'briefTitle': 'Diagnostic Markers of Neuropathic Odontalgia', 'organization': {'class': 'OTHER', 'fullName': 'Assistance Publique - Hôpitaux de Paris'}, 'officialTitle': 'Diagnostic Markers of Neuropathic Odontalgia : Proof of Concept Study', 'orgStudyIdInfo': {'id': 'AP-HP190545'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Immunostaining', 'type': 'OTHER', 'description': 'Immunostaining of oral mucosa/gingiva samples'}]}, 'contactsLocationsModule': {'locations': [{'zip': '75018', 'city': 'Paris', 'country': 'France', 'contacts': [{'name': 'Nathan MOREAU, DDS, PhD', 'role': 'CONTACT', 'email': 'nathan.moreau@aphp.fr', 'phone': '(0)1 53 11 14 18', 'phoneExt': '+33'}], 'facility': 'Bretonneau Hospital', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}], 'centralContacts': [{'name': 'Nathan MOREAU, DDS, PhD', 'role': 'CONTACT', 'email': 'nathan.moreau@aphp.fr', 'phone': '(0)1 53 11 14 18', 'phoneExt': '+33'}], 'overallOfficials': [{'name': 'Nathan MOREAU, DDS, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Assistance Publique - Hôpitaux de Paris'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Assistance Publique - Hôpitaux de Paris', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}